11 Oct 2024 • A large meta-analysis involving over 3.7 million obese adults has shown that metabolic-bariatric surgery (MBS) significantly lowers the risk of pancreatic cancer (PCa), regardless of type 2 diabetes (T2D) status.

Patients who underwent MBS had a 46% lower risk of PCa compared to those who did not, with the risk reduction more pronounced in T2D patients. Notably, sleeve gastrectomy showed the most dramatic impact on risk reduction, while Roux-En-Y bypass showed a less significant effect.

These findings underscore the potential of MBS as a critical intervention for reducing cancer risk in obese patients.

Source: Diabetes Metab Res Rev | Read full story